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Abstract
Background: Multiple single-nucleotide polymorphisms have been associated with low-density
lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglyceride (TG)
levels. In this paper, we evaluate a weighted and an unweighted approach for estimating the combined
effect of multiple markers (using genotypes and haplotypes) on lipid levels for a given individual.
Methods: Using data from the Framingham Heart Study SHARe genome-wide association study, we
tested genome-wide genotypes and haplotypes for association with lipid levels and constructed genetic
risk scores (GRS) based on multiple markers that were weighted according to their estimated effects on
LDL-C, HDL-C, and TG. These scores (GRS-LDL, GRS-HDL, and GRS-TG) were then evaluated for
associations with LDL-C, HDL-C, and TG, and compared with results of an unweighted method based
on risk-allele counts. For comparability of metrics, GRS variables were divided into quartiles.
Results: GRS-LDL quartiles were associated with LDL-C levels (p =2 . 1×1 0
-24), GRS-HDL quartiles
with HDL-C (p =5 . 9×1 0
-22), and GRS-TG quartiles with TG (p =5 . 4×1 0
-25). In comparison, these
p-values were considerably lower than those for the associations of the unweighted GRS quartiles for
LDL-C (p =3 . 6×1 0
-7), HDL-C (p =6 . 4×1 0
-16), and TG (p =4 . 1×1 0
-10).
Conclusion: GRS variables were highly predictive of LDL-C, HDL-C, and TG measurements,
especially when weighted based on each marker’s individual association with those intermediate
risk phenotypes. The allele-count GRS approach that does not weight the GRS by individual marker
associations was considerably less predictive of lipid and lipoprotein measures when the same
genetic markers were utilized, suggesting that substantially more risk-associated genetic marker
information is encapsulated by the weighted GRS variables.
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Low-density lipoprotein cholesterol (LDL-C), high-den-
sity lipoprotein cholesterol (HDL-C), and triglycerides
(TG) are accepted risk predictors for coronary artery
disease (CAD) [1,2]. Recently published genome-wide
association studies reported novel loci for LDL-C, HDL-
C, and TG, while also confirming several previously
described loci [3-5]. Those studies replicate each other
for many of the loci; however, it is unclear how the
combined effect of these markers for a given patient
should be estimated most effectively.
The genetic risk score (GRS) model is an approach for
evaluating multiple related markers simultaneously in
association testing for clinical phenotypes such as lipid
levels. A recent publication reported an unweighted,
integer-based GRS calculated as the sum of risk alleles
associated with LDL-C and HDL-C [6]. We previously
introduced the concept of aggregating polygenic infor-
mation in a GRS weighted by the estimated effect of each
marker on intermediate risk phenotypes [7]. For this
investigation, we hypothesized that the weighted GRS
approach would be more powerful than an integer-based
GRS because it accounts for variability in the effect of
each marker on the phenotype and thus may better
represent the complex physiology that drives changes in
lipid and lipoprotein levels.
Risk scores proposed thus far, including our own, are
based on modelling the contributions of multiple,
individual single-nucleotide polymorphisms (SNPs).
We hypothesized that haplotypes also are relevant for
identifying association evidence and that such biologi-
cally relevant markers are overlooked in single-marker
analyses. Hence, we also performed haplotype-based
association testing in regions where individual SNPs
were below the threshold for genome-wide significance
a n di n c l u d e dt h e s em a r k e r si nG R Sm o d e l s .
Using markers that individually were associated with
lipid/lipoprotein levels, we constructed weighted and
unweighted GRS metrics for individuals in the Framing-
ham Heart Study and estimated the ability of each
composite measure to predict lipid levels.
Methods
GAW16 data from Framingham Heart Study
For this analysis, SNP data from the Genetic Analysis
Workshop 16 (GAW16) Problem 2 (real phenotype
data) were utilized. These data arose from the Framing-
ham Heart Study SHARe genome-wide association study
that evaluated DNA markers for a large subset of the
Framingham Heart Study participants using the Affyme-
trix GeneChip® Human Mapping 500 k Array Set. The
data were hosted by and acquired through the NIH
dbGAP tool. This investigation was in compliance with
the Data Use Agreement required for access to this data
set as well as with the requirements of the University of
Utah’s Institutional Review Board.
Clinical data elements
The Framingham data set contained phenotypes for 373
individuals from the original cohort, 2,760 from the
offspring cohort, and 3,997 from the third generation.
Data elements for each participant were selected from
the first available study exam for which total cholesterol,
HDL-C, and TG levels were available. Because LDL-C
measurements were not provided, values were estimated
for each participant using the equation:
LDL C Total Cholesterol HDL C TG - - =− − ⋅ (. ) . 02
Of the 7,130 participants, 397 were excluded because of
missing measurements for cholesterol, HDL-C, or TG at
all available study visits.
Association testing
A genome-wide analysis was undertaken to test associa-
tion of genotypes and haplotypes with LDL-C, HDL-C,
and TG. Before this, an additional 322 individuals were
excluded because they reported medication use for the
treatment of dyslipidemia. Quality control also screened
out SNPs and participants with <98% genotyping
success and SNPs not in Hardy-Weinberg equilibrium
(p < 0.001). After filtering these individuals, 6,411
remained for association testing.
Genotypes were tested for association with each pheno-
type using two randomly assigned (on a per-individual
basis) subsets of the study population–one with n =
3,847 participants (60% of total population) and
another with n = 2,564 participants (40% of total
population). The purpose of dividing the data was to
select markers that could reach significance (though not
necessarily at a genome-wide level) in two samples. We
performed a quantitative association test using the
PLINK software [8] with default configuration settings
and a significance level of p < 0.001. SNPs identified in
this step were carried forward for use in the GRS models.
Haplotypes were constructed and tested for association
with each phenotype. The PLINK software [8] was used
on the full data set to identify SNPs that obtained a
p-value between 10
-2 and 10
-4. We chose this threshold
range with the goal of identifying SNPs that did not
reach genome-wide significance alone but that would be
substantially more significant as part of a haplotype. The
regions containing these SNPs were ranked using a
scoring metric that increased according to the
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-2 = +1, <10
-3 = +2,
or <10
-4= +3). After identification of an initial SNP with
a p-value between 10
-2 and 10
-4, the score for that region
was increased until 15 nearby SNPs failed to reach at
least a significance level of 10
-2. Haplotype analyses were
then pursued in the top ten scoring regions (which
spanned ~25 kilobases and contained ~7 SNP markers).
The haplotype analyses were performed using hapCon-
structor [9], which uses a forward-backward search
algorithm to construct haplotypes and test for associa-
tion. Its haplotype-mining technique starts with single
SNPs and builds up haplotypes SNP-by-SNP, searching
for the most significant haplotype across multiple
models (dominant, recessive, and additive). The SNP
sets considered need not be contiguous. It then uses a
difference-of-means test statistic to test for haplotype
associations and assesses significance via a Monte Carlo
approach (500,000 null simulations maximum). The
two most significant haplotypes for each phenotype were
used in the GRS models. The full data set was used for
identifying haplotypes due to the lack of a straightfor-
ward approach for combining results from two data
subsets.
Weighted GRS
GRS variables for each phenotype were calculated
separately for each participant (in the full data set),
including those on anti-dyslipidemia medications. TG
levels were natural-log transformed. The estimated effect
size for each genotype selected from the association
analysis described above was calculated as the mean
(median for TG) difference in lipid levels between those
with the wild-type variant and those homozygote for the
rare variant (effect = 0 for heterozygotes). For each
marker, wild-type, heterozygote, and homozygote reces-
sive genotype carriers received a score of -1, 0, or -1,
respectively, multiplied by the marker’s estimated effect
size. These scores were summed into a GRS for each
participant.
Due to the approximately continuous distribution of the
weighted GRS values, these variables were divided into
quartiles of similar sample size for the purposes of
comparing association statistics with those computed for
the unweighted GRS variable and to present the data in a
clinically relevant framework in which thresholds are
used for decision-making. Linear mixed models [10]
were used to test for association of GRS variables with
LDL-C, HDL-C, and TG, with family membership
included in each model as a random-effects variable to
adjust for pedigree membership. Multivariate analysis of
variance was also used to simultaneously model the
association of GRS-LDL, GRS-HDL, and GRS-TG with the
dependent variables LDL-C, HDL-C, and TG to compute
coefficients of determination that were comparable to
the unweighted GRS.
Unweighted GRS
The unweighted, risk-allele based GRS method [6] is
calculated for each participant as the sum of risk allele
counts across each marker that predicts LDL-C, HDL-C,
or TG. This unweighted GRS was composed using the
same markers as the weighted analysis and was evaluated
o nt h es a m ed a t as e to fp a r t i c i p a n t s .A n ym a r k e r
associated with multiple lipid/lipoprotein phenotypes
was included only once in the summation. A value of 0,
1, or 2 was assigned to each SNP based on carriage of the
same number of copies of the risk allele. These values
were then summed for each participant and divided into
quartiles for comparative purposes. Association of this
GRS with LDL-C, HDL-C, and TG was performed as
above using a linear mixed model and coefficients of




For LDL-C, six SNPs reached p < 0.001 in both data
subsets (Table 1). SNPs associated with HDL-C at
p < 0.001 in both subsets included 11 SNPs on
chromosome 8p21 that defined two haplotypes in the
region 3’ to the LPL gene. A single SNP in each of these
haplotypes was sufficient to explain >90% of the
haplotypic variance, and thus represented the haplotype
in the GRS. Nine SNPs had p < 0.001 in both subsets
for TG. Of these SNPs, rs599839 had the strongest
individual association with any phenotype (LDL-C),
obtaining a p-value of 9.5 × 10
-13 in the first data subset
and 2.2 × 10
-16 in the entire data set.
For all three phenotypes, a number of regions existed
where haplotype associations were an order of magni-
tude more significant than any single SNP in the region.
For HDL-C, seven haplotypes achieved p <1 0
-4,a n do n e
haplotype attained a p-value of 8.0 × 10
-6.F o rL D L - C ,
two haplotypes reached p <1 0
-4. For TG, two haplotypes
reached p ≤ 6 . 0×1 0
-4. For the latter two phenotypes, no
haplotype attained a p-value less than 10
-5. The results
for the top two haplotypes associated with each
phenotype are listed in Table 2.
GRS association
Table 3 shows the results of testing for association
between the weighted GRS and lipid/lipoprotein levels.
The GRS for each phenotype was associated far more
strongly than the association that was observed for the
phenotype with any individual marker (compare with
Table 1). Some weak cross-association was seen for
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and for GRS-TG with HDL-C.
Table 4 shows the association results for the unweighted
GRS. It is of note that the association with LDL-C would
not have achieved genome-wide significance if it had
been a single marker. The lower predictive ability of the
unweighted GRS is understandable given the integer-
based composition and the lower range of 6-20. (See
Table 4. Compare this with the range of values for GRS-
LDL, GRS-HDL, and GRS-TG in Table 3).
Coefficients of determination for the unweighted GRS
were r
2 = 0.007, 0.016, and 0.010 for LDL-C, HDL-C, and
Table 1: SNPs associated with LDL-C, HDL-C, and TG in GWAS, with the gene that they are in or near
p-Value




b rs599839 1p13 9.5 × 10
-13 1.6 × 10
-6 2.2 × 10
-16 -16.7
CELSR2
b rs4970834 1p13 5.6 × 10
-7 6.8 × 10
-5 1.1 × 10
-9 -10.3
PSMA5 rs17586966 1p13 1.8 × 10
-5 3.6 × 10
-4 2.8 × 10
-7 -8.8
MTPN rs1365360 7q33 4.2 × 10
-4 7.8 × 10
-4 1.4 × 10
-6 7.7
DCDC1/5 rs158584 11p14 2.7 × 10
-4 5.3 × 10
-4 2.3 × 10
-7 7.1
RORA rs782918 15q22 3.2 × 10
-4 6.3 × 10




c rs17482753 8p21 5.4 × 10
-10 9.2 × 10
-6 5.5 × 10
-13 11.1
LPL rs10503669 8p21 1.1 × 10
-9 4.9 × 10
-6 2.5 × 10
-13 12.4
LPL rs17410962 8p21 7.4 × 10
-8 2.9 × 10
-5 6.9 × 10
-11 8.5
LPL rs17489268 8p21 1.1 × 10
-9 3.5 × 10
-6 6.6 × 10
-15 4.5
LPL rs17411024 8p21 4.6 × 10
-8 1.5 × 10
-5 1.6 × 10
-11 5.5
LPL rs17411031 8p21 2.1 × 10
-9 3.2 × 10
-6 1.3 × 10
-14 4.5
LPL rs17411126 8p21 3.3 × 10
-9 7.7 × 10
-6 6.1 × 10
-14 4.4
LPL rs765547 8p21 4.3 × 10
-9 6.1 × 10
-6 4.6 × 10
-14 4.5
LPL rs11986942 8p21 1.1 × 10
-6 4.0 × 10
-4 3.1 × 10
-9 3.6
LPL rs1837842 8p21 4.9 × 10
-9 1.8 × 10
-6 1.7 × 10
-14 4.6
LPL rs1919484 8p21 5.9 × 10
-9 2.7 × 10
-6 3.2 × 10
-14 4.6
CETP
c rs9989419 16q13 1.1 × 10
-4 4.6 × 10
-4 8.2 × 10
-7 -3.6
LIPG
b rs7240405 18q21 1.0 × 10
-4 6.9 × 10
-4 5.3 × 10
-7 -3.6
LIPG rs4939883 18q21 2.9 × 10
-5 6.2 × 10
-4 1.7 × 10
-7 -3.6
ACAA2
b rs6507945 18q21 4.6 × 10
-4 1.0 × 10
-4 6.8 × 10
-7 -3
Triglycerides
SUMF1 rs317608 3p26 5.7 × 10
-4 1.4 × 10
-4 4.0 × 10
-7 26
RASGEF1B rs4382026 4q21 6.3 × 10
-4 3.6 × 10
-5 5.3 × 10
-9 22
BAZ1B rs2074755 7q11 1.4 × 10
-5 2.0 × 10
-4 3.9 × 10
-10 -13
LPL
c rs17489268 8p21 1.5 × 10
-6 1.6 × 10
-4 9.8 × 10
-12 -13
LPL rs17411031 8p21 9.3 × 10
-7 1.6 × 10
-4 6.0 × 10
-12 -13
LPL rs17411126 8p21 1.4 × 10
-6 2.0 × 10
-4 1.3 × 10
-11 -13
LPL rs765547 8p21 3.6 × 10
-6 4.9 × 10
-4 6.9 × 10
-11 -13
LPL rs1837842 8p21 4.8 × 10
-6 3.4 × 10
-4 7.1 × 10
-11 -13
LPL rs1919484 8p21 1.7 × 10
-5 3.3 × 10
-4 3.6 × 10
-10 -12
aEffect sizes given here are the difference in the mean (TG: median) between the homozygote recessive genotype and homozygote wild-type.
bSee Kathiresan et al. [5].
cSee Purcell et al. [8].
Table 2: The two most significant haplotypes
a for each phenotype
Phenotype Chr SNPs Haplotype Model p-Value Effect size
b
HDL-C 5 rs922556, rs10070979 1-2 Dominant 8.0 × 10
-6 -16.1 mg/dL
HDL-C 3 rs2724721, rs384828 2-2 Dominant 5.1 × 10
-4 -1.9 mg/dL
LDL-C 6 rs316024, rs576075, rs614564, rs533452 2-1-1-1 Dominant 5.3 × 10
-5 3.4 mg/dL
LDL-C 7 rs4947934, rs4947936 2-1 Additive 6.0 × 10
-5 16.4 mg/dL
TG 3 rs7645357, rs4685635 2-2 Additive 5.0 × 10
-4 -9.0 mg/dL
TG 10 rs603269, rs475945 2-2 Additive 6.0 × 10
-4 3.0 mg/dL
aSNPs with p <1 0
-2 and p >1 0
-4 were used to construct haplotypes and associations were tested in hapConstructor [9].
bMean (TG: median) difference for listed haplotype vs. most common haplotype.
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GRS-HDL, and GRS-TG showed r
2 = 0.025, 0.023, and
0.024 for LDL-C, HDL-C, and TG. Although low (but not
much lower than a recent report using 30 SNPs [11] that
showed r
2 = 0.06-0.09), r
2 was greater for the weighted
GRS approach.
GRS associations using the weighted GRS methods and
including the two best haplotype markers for LDL-C, HDL-
C, and TG provided marked improvement (Table 5) in the
association of GRS-LDL with LDL-C (p =6 . 0×1 0
-28)a n d
GRS-HDL with HDL-C (p =6 . 2×1 0
-25), but not for GRS-
TG with TG (p =6 . 7×1 0
-23, which is lower than the GRS
that did not use haplotype markers [see Table 3]). Changes
in associations due to inclusion of haplotype markers were
on the order of 10
-4 for GRS-LDL with LDL-C, 10
-3 for
GRS-HDL with HDL-C, and 10
1 for GRS-TG with TG.
Discussion
Many SNPs influence lipid and lipoprotein levels [12].
This study of GRS models illustrates the potential to
stratify genetic risk for complex phenotypes by account-
ing for polygenic effects. Aggregating data from many
markers into a single GRS variable allows genetic and
biological information related to a phenotype to be
condensed into a statistical metric of low dimension-
ality.
We identified multiple SNPs that were associated
(p < 0.001) with lipid levels in two data subsets. Most
of these attained genome-wide statistical significance in
the full data set, even after a conservative Bonferroni
correction. The weighted GRS variables were associated
with the phenotypes at a substantially better significance
level (lower p-value), supporting the concept that a score
based on multiple SNPs may be used effectively to
represent the joint contributions of components in the
underlying biological pathway.
In this study, the associations with LDL-C, HDL-C, and
TG were greater for the weighted GRS than for the
unweighted GRS, a single composite metric based only
on risk-allele carriage. GRS metrics that use only the
carriage of risk alleles may account only for the presence
and not the relative value of those alleles [6,13]. While
shown here and previously [6,13] to have some value, in
an unweighted GRS the relative contribution of indivi-
dual genetic markers is ignored, thus treating each as
equal in effect and potentially mis-specifying the actual
risk relationship. Based on these results, our weighted
Table 3: Weighted GRS results and GRS associations with lipid/lipoprotein levels
a
Mean (LDL-C & HDL-C)/median (TG) in GRS by quartile
G R S M i n M a x M e a n S . D . 1234 p-Value
GRS-LDL -34.8 15 -2.69 6.8
LDL-C 107.2 115.8 118.1 122.2 2.1 × 10
-24
HDL-C 53.9 53.5 52.3 53.0 0.07
TG 81.0 83.0 83.0 81.0 0.04
GRS-HDL -10.2 17 -1.28 3.5
LDL-C 116.1 116.3 117.2 115.1 0.6
HDL-C 50.5 51.7 54.3 56.2 5.9 × 10
-22
TG 83.0 87.0 84.0 76.0 3.4 × 10
-6
GRS-TG -26.0 31 -2.10 8
LDL-C 115.1 116.6 117.4 115.5 0.43
HDL-C 54.9 54.1 51.5 52.5 7.7 × 10
-9
TG 72.0 79.0 86.0 94.0 5.4 × 10
-25
aResults of association testing using a linear mixed model with family membership included in the model as a random-effects variable. Phenotype
values are in mg/dL.
Table 4: Unweighted GRS (sum of risk alleles carried, as defined in literature reports [6]) and its association with lipid/lipoprotein
levels
a
Number of risk alleles carried Mean (LDL-C & HDL-C)/median (TG) in GRS by quartile
GRS Min Max Mean S.D. 1 2 3 4 p-Value
6 20 12.8 2.1
LDL-C 112.8 113.4 117.9 119.9 3.6 × 10
-7
HDL-C 56.2 53.8 51.8 51.2 6.4 × 10
-16
TG 75.0 84.0 84.0 87.0 4.1 × 10
-10
aResults of association testing using a linear mixed model with family membership included in the model as a random-effects variable. Phenotype
values are in mg/dL.
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extract clinically meaningful genetic information for a
risk pathway and encapsulate it into a useful, low-
dimension variable.
In this study, each weighted GRS showed strong
association with its target phenotype. Though they likely
would not supplant the need for standard serum
measurements of lipid and lipoprotein levels, these
GRSs potentially could be useful in identifying indivi-
duals early in life who are at increased lifetime risk,
which can lead to advanced phenotypes such as CAD
[1,2]. Clinicians potentially could also use the GRS
information to better target medical therapies and
diagnostic screening for preventive purposes. This
analysis also suggests that a GRS approach may be
more useful and effective at characterizing risk of
coronary heart disease endpoints than individual genetic
markers, although this remains to be tested.
This study has several limitations. The GRS models were
evaluated on the same data set on which association
testing and construction of the models were performed.
This likely led to over-fitting of the models, potentially
biasing significance levels for the GRS association
testing. However, both the weighted and unweighted
GRS models would be affected by this bias and thus the
comparisons between them should remain valid.
Further, the genome-wide association analyses using
PLINK were done using a naïve approach that did not
account for the family structure in the Framingham
Heart Study data. In a study based on these data, some of
the authors report in another GAW16 paper [14] that
even though a naïve approach is anti-conservative, the
results from an empirical analysis would have been
highly correlated with the results of this naïve approach.
Conclusion
GRS variables aggregating genetic and intermediate risk
phenotype information were highly predictive of LDL-C,
HDL-C, and TG measurements, and these associations
were improved with inclusion of haplotype information
at loci for which SNPs had only weak associations.
Summation of risk alleles in an integer-based
unweighted GRS were substantially less predictive of
the lipid/lipoprotein phenotypes.
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